Announcement according to Article 17 European Market Abuse Regulation (MAR)
Dr Michael Ramroth to become new CEO of Biotest AG
Dreieich, 7 March 2019. The Supervisory Board of Biotest AG, in its meeting today, appointed Dr. Michael Ramroth (58) as Chairman of the Board of Management (CEO) effective May 1st, 2019. He will take over the role as CEO from Dr. Bernhard Ehmer (64) whose appointment will then end after four and a half years for reasons of age.
Dr Ramroth has been a member of the Board of Management of Biotest AG since 2004. He joined Biotest from a position as Chairman for Business Development at Metallgesellschaft Technologies AG. From 1999 he had worked as CFO for the same company. From 1997 to 1999 he was CEO of CeramTec AG and from 1990 to 1997 Director of Business Development at Metallgesellschaft AG. Dr Ramroth is a lawyer and has a doctorate in economics.
Besides Dr Michael Ramroth as CEO, Dr Georg Floss will continue to be a member of the Board of Management of Biotest as COO. Dr Floss will assume additional responsibilities starting May 1st, 2019.
Biotest AG is very pleased that Dr Bernhard Ehmer will be available for consulting services in strategic projects.
Board of Management
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition, Biotest develops monoclonal antibodies in certain cancer indications and in systemic lupus erythematodes, an autoimmune disease, which are produced by recombinant technologies. Biotest has more than 1,600 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.
Dr Monika Buttkereit
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com
Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate
Dr. Michael Ramroth
Chief Financial Officer
Tel. +40 6103 801 338
Fax: +49 6103 801 347
07-March-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de